Skip to content

Disease‑Modifying Therapy for Ocular Surface Disease

While 17.8 million people have been diagnosed with Dry Eye Disease in the United States…

Fewer than 1 million (1 in 20) are currently treated with an FDA-approved product; presumably due to questionable efficacy and tolerability limitations.

Patients infographic

Less than 5% (1 in 20) of Dry Eye Disease patients are currently treated with a FDA-approved product

Aramis Biosciences is a clinical-stage immuno‑ophthalmology biopharmaceutical company committed to the development of disease‑modifying therapy for ocular surface disease

Learn more about Aramis Biosciences

Get in touch

Please provide a brief description of your inquiry and we’ll get back to you as soon as we can.